24/7 Wall Street
24 Sept 2025, 20:13 UTC · 51w ago
Verdict
Headline leans bearish. We score ETR +0.80 across three claims.
Score contradicts the headline.
Leans bearish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish
JPMorgan projects U.S. GDP growth will slow to a 1.2% annualized rate in Q4 2025 and Q1 2026.
More negative than 92% of claims this week
JPMorgan attributes the projected economic slowdown to the potential impact of U.S. tariffs, which could act as a $430 billion tax hike.
Continue reading
5 related stories
More positive than 87% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 86% of claims this week
JPMorgan suggests high-yield value dividend stocks are positioned to outperform as interest rates decline over the next year.
More positive than 65% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
Called a top utility stock that makes sense for conservative investors with a J.P. Morgan price target of $103.
More positive than 87% of ticker scores this week
Described as a no-brainer healthcare giant with a solid dividend and a target price of $120.
More positive than 81% of ticker scores this week
Identified as offering an incredible entry point and a solid dividend.
More positive than 69% of ticker scores this week
Described as an acknowledged leader with a top-notch research department.
More positive than 52% of ticker scores this week
Mentioned positively in the context of strategic collaborations for HIV treatments.
More positive than 52% of ticker scores this week
Mentioned positively in the context of strategic collaborations for HIV treatments.
More positive than 52% of ticker scores this week
Mentioned positively in the context of strategic collaborations for HIV treatments.
Near neutral — 90% of ticker scores this week are stronger
Mentioned only as a historical reference for an analyst's past success.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Barrons
42m ago
More positive than 34% of relationship scores this week
[mutual] Merck works with Bayer to jointly develop and commercialize long-acting treatments for HIV.
More positive than 34% of relationship scores this week
[mutual] Merck works with Eisai to jointly develop and commercialize long-acting treatments for HIV.
More positive than 34% of relationship scores this week
[mutual] Merck works with Gilead Sciences to jointly develop and commercialize long-acting treatments for HIV.
+11.7%
Price agrees with the score
$102.32 vs $91.59 close before publication (Sep 24) · not market-adjusted
ETR chart →
